Selinexor (KPT-330) in Older Patients With Relapsed AML

• Status: Completed
• Trial end date: 2018-01-08
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, multicenter, open-label, phase 2 study of the SINE compound, selinexor given orally versus specified investigator choices (one of three potential salvage therapies). Participants age ≥ 60 years with relapsed or refractory AML of any type except for AML M3, after one prior therapy only, who have never undergone and who are not currently eligible for stem cell transplantation and are currently deemed unfit for intensive chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karyopharm Therapeutics Inc; Karyopharm Therapeutics, Inc
• Treatments: Azacitidine; Cytarabine; Decitabine; Hydroxyurea

Criteria

Inclusion Criteria:

• Age ≥ 60 years with relapsed or refractory AML of any type except for acute promyelocytic leukemia (APL; AML M3), after at least 1 prior AML therapy , who have never undergone, and who are not currently eligible for, stem cell transplantation, and are currently deemed unfit for intensive chemotherapy.

• Eastern Cooperative Oncology Group (ECOG) ≤ 2.

• Must have available archival or recently acquired bone marrow biopsy/aspiration or tumor tissue for central review to be eligible.

• Relapsed or refractory AML, defined as either: recurrence of disease after a complete remission (CR), or failure to achieve CR with initial therapy.

• Must have received at least 1 prior line of AML therapy given at standard doses and must have progressed after their most recent therapy. Prior therapy must have included: a hypomethylating agent with at least 2 cycles.

• At least 2 weeks must have elapsed since the last anti-leukemia treatment (with the exception of hydroxyurea) before first dose in this study.

Exclusion Criteria:

• Treatment with any investigational agent within 3 weeks prior to first dose in this study.

• Presence of central nervous system (CNS) leukemia.

• In blast transformation of chronic myeloid leukemia (CML). Prior myelodysplastic syndrome (MDS) is acceptable; prior treatment for MDS does not count as an AML therapy.

• Major surgery within 2 weeks of first dose of study drug. Participants must have recovered from the effects of any surgery performed greater than 2 weeks previously.

• Concurrent active malignancy under treatment.

• Known active hepatitis B virus (HBV) or C virus (HCV) infection; or known to be positive for HCV ribonucleic acid (RNA) or HBsAg (HBV surface antigen).

• Known HIV infection.

• Unable to swallow tablets, or participants with malabsorption syndrome, or any other disease significantly affecting gastrointestinal function.

• Participants whose AML is classified as favorable according to the European LeukemiaNet (ELN) disease risk assessment.